Monoclonal antibodies neutralizing circulating SARS-CoV-2 variants of concern

0576962 - BC 2024 RIV US eng A - Abstract
Kováčech, B. - Fialova, L. - Filipčík, P. - Škrabana, R. - Zilkova, M. - Kovac, A. - Rolkova, G.P. - Tomková, K. - Csokova, N. - Markova, K. - Skrabanova, M. - Majerova, P. - Hanes, J. - Cehlar, O. - Cente, M. - Piešťanský, J. - Slávikova, M. - Borsova, K. - Čabanová, V. - Brejová, B. - Vinař, T. - Nosek, J. - Klempa, B. - Eyer, Luděk - Hönig, Václav - Palus, Martin - Růžek, Daniel - Vyhlídalová, Tereza - Straková, Petra - Mrázková, Blanka - Zudová, Dagmar - Koubková, Gizela - Novosadová, Vendula - Procházka, Jan - Sedláček, Radislav - Žilka, N. - Kontsekova, E.
Monoclonal antibodies neutralizing circulating SARS-CoV-2 variants of concern.
European Journal of Immunology. Wiley. Roč. 53 (2023), s. 53-54. ISSN 0014-2980. E-ISSN 1521-4141.
[5th Annual Meeting of Middle-Europe-Societies-of-Immunology-and-Allergology (MESIA). 23.11.2022-26.11.2022, Praha]
Institutional support: RVO:60077344 ; RVO:68378050
Keywords : Monoclonal * SARS-CoV-2 * circulating
OECD category: Immunology
https://onlinelibrary.wiley.com/doi/epdf/10.1002/eji.202370200

Variants of the SARS-CoV-2 virus emerge while it circulates within human population. They carry mutations mostly localized to the Spike protein, which drives viral entry into mammalian cells, and thus allow the virus to escape the neutralizing activities of the host’s immune system. The repeated emergence of the variants raised concern about the activities of current vaccines and therapeutic antibodies, some of which have shown drastically reduced efficacy.
Permanent Link: https://hdl.handle.net/11104/0346792